AbCellera Biologics Inc. (ABCL)
NASDAQ · Healthcare
AbCellera Biologics Inc. Operating Income 2019–2025
AbCellera Biologics Inc. annual/quarterly operating income history and growth rate from 2019 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- AbCellera Biologics Inc. operating income for the quarter ending March 31, 2026 was -57.5 M, a 8.20% decrease year-over-year.
- AbCellera Biologics Inc. operating income for the twelve months ending March 31, 2026 was -246.0 M, a 17.13% decrease year-over-year.
- AbCellera Biologics Inc. annual operating income for 2025 was -217.1 M, a 31.03% decrease from 2024.
- AbCellera Biologics Inc. annual operating income for 2024 was -314.8 M, a 32.70% increase from 2023.
- AbCellera Biologics Inc. annual operating income for 2023 was -237.2 M, a 209.56% decrease from 2022.
- AbCellera Biologics Inc. annual operating income for 2022 was 216.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
AbCellera Biologics Inc. Operating Income — FAQ
AbCellera Biologics Inc. (ABCL) operating income over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
What is AbCellera Biologics Inc.'s operating income?
AbCellera Biologics Inc. (ABCL) reported operating income of -$217M for fiscal 2025.
Where can I see ABCL's operating income history?
The chart and table above show AbCellera Biologics Inc.'s operating income by year and by quarter, including the growth rate.